表紙
市場調査レポート

イダルビシンの中国市場

Investigation Report on China Idarubicin Market, 2010-2019

発行 China Research and Intelligence 商品コード 337521
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
イダルビシンの中国市場 Investigation Report on China Idarubicin Market, 2010-2019
出版日: 2015年08月18日 ページ情報: 英文 30 Pages
概要

イダルビシンはイタリアのArca-moneによって開発されたダウノルビシンの類似体で、DNAの巻き戻しを防止する効果があります。L1210白血病やP338白血病、グロス白血病に対して効果的で、毒性も低いとの結果が出ています。中国国内での販売額は、2005年の1400万人民元から、2014年には8000万人民元にまで拡大しました。

当レポートでは、中国におけるイダルビシンの市場について分析し、イダルビシンの特徴や認証状況、全体的な市場規模、企業別・剤形別の市場シェア、価格動向、主要メーカーのプロファイル、今後の市場成長の見通しなどについて調査・推計しております。

第1章 イダルビシンの関連概念

  • 適応症
  • 世界市場での販売状況

第2章 中国のイダルビシン市場のプロファイル

  • 中国国内でのイダルビシンの特許申請・承認状況
  • 主要メーカー
  • 市場規模

第3章 中国国内のイダルビシン販売額の分析 (過去5年間分)

  • 販売額
    • 全体的な販売額
    • 地域別の販売額
  • 販売量
    • 全体的な販売量
    • 地域別の販売量

第4章 イダルビシンの主要メーカーの市場シェア (過去5年間分)

  • 市場シェア (金額ベース)
  • 市場シェア (数量ベース)

第5章 中国国内でのイダルビシンの剤形 (過去5年間分)

  • 剤形別の市場シェア (金額ベース)
  • 剤形別の市場シェア (数量ベース)

第6章 中国の病院におけるイダルビシンの参照価格

  • Pfizer Hisun Pharmaceutical Co., Ltd
  • Pharmacia&Upjohn (イタリア)
  • Pharmacia&Upjohn (Suzhou) Pharmaceutical Co., Ltd
  • Pfizer Inc. (イタリア)

第7章 中国国内のイダルビシンの主要メーカー (過去5年間分)

  • Pfizer Hisun Pharmaceutical Co., Ltd
  • Pharmacia&Upjohn (イタリア)
  • Pfizer Inc. (イタリア)
  • Nerviano Medical Science S.r.l. (イタリア)

第8章 中国国内のイダルビシン市場の将来展望 (今後5年間分)

  • 市場規模の予測
  • 競争環境の予測

図表一覧

目次
Product Code: 1508304

The exact cause of leukemia is yet to be identified with interior decoration pollution, ionizing radiation, drug contamination and virus infection all being the suspect. The increasing incidence of leukemia is growing in China and the number of new cases reaches 40000 each year, among which over 85% belongs to acute leukemia.

Developed by Italian Arca-mone, idarubicin is an analog of daunorubicin with higher fat solubility. Its main metabolite works by preventing DNA unwinding. In preliminary studies, idarubicin turns out to be more effective and less toxic than DNR and DXR in treating L1210 leukemia, P338 leukemia and Gross leukemia. Since 1988, Japan has conducted clinical research on acute leukemia.

As an anti-mitosiss agent, idarubicin is used in the first line treatment of acute nonlymphoblastic leukemia (ANLL) relapse remission and the second line treatment of acute lymphoblastic leukemia (ALL).

According to CRI's market survey, idarubicin enjoys an increasing demand in China with sales value rising from about CNY 14 million in 2005 to over CNY 80 million in 2014 and CAGR during the period of 2010-2014 reaching 22%. And Pfizer Hisun Pharmaceutical Co., Ltd, Pharmacia&Upjohn (IT), Pharmacia&Upjohn (Suzhou) Pharmaceutical Co., Ltd, Pfizer Inc. (IT) and Nerviano Medical Science S.r.l. (IT) occupy the market, among which Pfizer Hisun Pharmaceutical Co., Ltd had the largest market share of over 40% for sales value in 2014.

Research has shown that autologus hematopoietic stem cell transplantation (HSCT) is an effective way to treat ALL. As idarubicin is included in autologus HSCT, its future demand is expected to be great.

Readers can get at least the following information through this report:

  • market size of idarubicin in China
  • competitive landscape of idarubicin market in China
  • price of idarubicin made by different enterprises in China
  • market outlook of idarubicin in China

The author suggests the following groups of people purchase this report:

  • manufacturers of antileukemic agents
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Idarubicin

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Idarubicin in China

  • 2.1. Patent and Approval Information of Idarubicin in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Idarubicin Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Idarubicin Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Idarubicin in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Idarubicin in Chinese Hospitals in 2014

  • 6.1. Pfizer Hisun Pharmaceutical Co., Ltd
  • 6.2. Pharmacia&Upjohn (Italy)
  • 6.3. Pharmacia&Upjohn (Suzhou) Pharmaceutical Co., Ltd
  • 6.4. Pfizer Inc. (Italy)

7. Major Manufacturers of Idarubicin in Chinese Market, 2010-2014

  • 7.1. Pfizer Hisun Pharmaceutical Co., Ltd
  • 7.2. Pharmacia&Upjohn (Italy)
  • 7.3. Pfizer Inc. (Iyaly)
  • 7.4. Nerviano Medical Science S.r.l. (Italy)

8. Market Outlook of Idarubicin in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Idarubicin in China
  • Chart Idarubicin Sales in China
  • Chart Sales Value of Idarubicin in China, 2010-2014
  • Chart Sales Value of Idarubicin in Some Regions in China, 2010-2014
  • Chart Sales Volume of Idarubicin in China, 2010-2014
  • Chart Sales Volume of Idarubicin in Some Regions in China, 2010-2014
  • Chart Market Share of TOP5 Idarubicin Enterprises for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Idarubicin Made by Pfizer Hisun in China, 2010-2014
  • Chart Sales Value and Market Share of Idarubicin Made by Pharmacia&Upjohn (IT) in China, 2010-2014
  • Chart Sales Value and Market Share of Idarubicin Made by Pharmacia&Upjohn (Suzhou) in China, 2010-2014
  • Chart Sales Value and Market Share of Idarubicin Injection in China, 2010-2014
  • Chart Sales Value and Market Share of Idarubicin Capsule in China, 2010-2014
  • Chart Price of Idarubicin Made by Pfizer Hisun Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Idarubicin Made by Pharmacia&Upjohn (IT) in Some Chinese Cities in 2014
  • Chart Price of Idarubicin Made by Pharmacia&Upjohn (Suzhou) in Some Chinese Cities in 2014
  • Chart Price of Idarubicin Made by Pfizer (IT) in Some Chinese Cities in 2014
  • Chart Price of Idarubicin Made by Nerviano Medical Science S.r.l. (IT) in Some Chinese Cities in 2014
Back to Top